JPMorgan Chase & Co. Sells 2,773 Shares of VanEck Biotech ETF (NASDAQ:BBH)

JPMorgan Chase & Co. trimmed its holdings in shares of VanEck Biotech ETF (NASDAQ:BBH) by 18.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,072 shares of the company’s stock after selling 2,773 shares during the period. JPMorgan Chase & Co. owned approximately 0.48% of VanEck Biotech ETF worth $2,141,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Truvestments Capital LLC bought a new position in shares of VanEck Biotech ETF during the 3rd quarter worth approximately $44,000. FSA Wealth Management LLC acquired a new position in shares of VanEck Biotech ETF during the third quarter worth approximately $54,000. Coastline Trust Co acquired a new position in shares of VanEck Biotech ETF during the third quarter worth approximately $59,000. Wilmington Savings Fund Society FSB acquired a new position in shares of VanEck Biotech ETF during the third quarter worth approximately $166,000. Finally, Tyler Stone Wealth Management raised its position in shares of VanEck Biotech ETF by 79.5% during the third quarter. Tyler Stone Wealth Management now owns 1,472 shares of the company’s stock worth $261,000 after purchasing an additional 652 shares during the period. 32.05% of the stock is currently owned by institutional investors.

VanEck Biotech ETF Stock Up 2.4 %

Shares of NASDAQ:BBH opened at $162.00 on Wednesday. VanEck Biotech ETF has a twelve month low of $151.35 and a twelve month high of $183.64. The stock’s 50 day moving average is $161.62 and its 200-day moving average is $171.44.

VanEck Biotech ETF Dividend Announcement

The company also recently announced a dividend, which was paid on Tuesday, December 24th. Stockholders of record on Monday, December 23rd were given a dividend of $1.2517 per share. The ex-dividend date was Monday, December 23rd.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.